search
Back to results

Progesterone Supplementation in Frozen Embryo Transfer Cycles

Primary Purpose

Infertility Due to Nonimplantation, Infertility

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Prometrium
Sponsored by
Mount Sinai Hospital, Canada
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Infertility Due to Nonimplantation

Eligibility Criteria

18 Years - 55 Years (Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • Patient at Mount Sinai Fertility who wants to undertake a frozen embryo transfer
  • History of recurrent implantation failure, defined as no pregnancy after three or more embryo transfers of four or more good quality blastocysts

Exclusion Criteria:

  • Previous testing with Endometrial Receptivity Assay (ERA)
  • Unable understand/communicate in English

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Active Comparator

    Experimental

    Arm Label

    Control Group

    Experimental Group

    Arm Description

    This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.

    This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).

    Outcomes

    Primary Outcome Measures

    clinical pregnancy rate
    Rate of pregnancy, evidenced by clinical (fetal heartbeat) or ultrasound parameters (ultrasound visualization of a gestational sac, embryonic pole with heartbeat). It includes ectopic pregnancy.

    Secondary Outcome Measures

    Live birth rate
    Rate of birth in which a fetus is delivered with signs of life after complete expulsion or extraction from its mother, beyond 20 completed weeks of gestational age
    Miscarriage rate
    Rate of natural death of embryo or fetus, after reaching clinical pregnancy stage and at or before 10 weeks gestation.

    Full Information

    First Posted
    April 12, 2018
    Last Updated
    April 12, 2018
    Sponsor
    Mount Sinai Hospital, Canada
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT03504345
    Brief Title
    Progesterone Supplementation in Frozen Embryo Transfer Cycles
    Official Title
    Assessing the Optimal Duration of Progesterone Supplementation Prior to Transfer of Frozen Embryos in the Recurrent Implantation Failure Population
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    April 2018
    Overall Recruitment Status
    Unknown status
    Study Start Date
    May 2018 (Anticipated)
    Primary Completion Date
    April 2019 (Anticipated)
    Study Completion Date
    July 2019 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Mount Sinai Hospital, Canada

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    No

    5. Study Description

    Brief Summary
    Recurrent implantation failure (RIF) occurs after women undergo in vitro fertilization and have multiple embryos transferred but no resulting pregnancies. RIF is a very challenging clinical entity for the reproductive physician and the patient. In fact, there is not even an agreed upon definition in the medical community. Many potential causes have been investigated over the past several years but no clear answer has emerged. Interest has recently turned to the endometrium, or the lining of the uterus. Studies have shown that the genes that are turned on in the endometrium vary based on how long this tissue has been exposed to progesterone, an important hormone that prepares the uterine lining for implantation of the growing embryo. In some women, it seems that they require longer periods of progesterone exposure to reach the same state of readiness. We hypothesize that an even larger proportion of women in RIF population will require longer treatments with progesterone. In this study, we will randomize women with RIF who are about to undergo a frozen embryo transfer to one of two groups. The first group will have their embryo transfer done on the standard sixth day of progesterone treatment. The other group will have their transfer done on the seventh day of progesterone. We will be comparing the clinical pregnancy rate of the two groups as well as the live birth rate and miscarriage rate. We expect that extending the progesterone treatment by one day will increase the pregnancy rate of women with RIF.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Infertility Due to Nonimplantation, Infertility

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    240 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    Control Group
    Arm Type
    Active Comparator
    Arm Description
    This arm of the study will have their frozen-thawed embryo transfer take place on the sixth day of progesterone supplementation (Prometrium), which is the standard protocol in our clinic.
    Arm Title
    Experimental Group
    Arm Type
    Experimental
    Arm Description
    This arm of the study will have their frozen-thawed embryo transfer take place on the seventh day of progesterone supplementation (Prometrium).
    Intervention Type
    Drug
    Intervention Name(s)
    Prometrium
    Intervention Description
    The intervention will involve delaying the transfer of a frozen-thawed embryo into the uterus to increase the duration of progesterone exposure.
    Primary Outcome Measure Information:
    Title
    clinical pregnancy rate
    Description
    Rate of pregnancy, evidenced by clinical (fetal heartbeat) or ultrasound parameters (ultrasound visualization of a gestational sac, embryonic pole with heartbeat). It includes ectopic pregnancy.
    Time Frame
    6 to 8 weeks after embryo transfer
    Secondary Outcome Measure Information:
    Title
    Live birth rate
    Description
    Rate of birth in which a fetus is delivered with signs of life after complete expulsion or extraction from its mother, beyond 20 completed weeks of gestational age
    Time Frame
    Approximately 9 months after embryo transfer
    Title
    Miscarriage rate
    Description
    Rate of natural death of embryo or fetus, after reaching clinical pregnancy stage and at or before 10 weeks gestation.
    Time Frame
    Approximately 3 months after embryo transfer

    10. Eligibility

    Sex
    Female
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    55 Years
    Accepts Healthy Volunteers
    Accepts Healthy Volunteers
    Eligibility Criteria
    Inclusion Criteria: Patient at Mount Sinai Fertility who wants to undertake a frozen embryo transfer History of recurrent implantation failure, defined as no pregnancy after three or more embryo transfers of four or more good quality blastocysts Exclusion Criteria: Previous testing with Endometrial Receptivity Assay (ERA) Unable understand/communicate in English
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Crystal Chan, MD, MSc, FRCSC
    Phone
    416-586-4800
    Ext
    6024
    Email
    crystal.chan@sinaihealthsystem.ca

    12. IPD Sharing Statement

    Plan to Share IPD
    No

    Learn more about this trial

    Progesterone Supplementation in Frozen Embryo Transfer Cycles

    We'll reach out to this number within 24 hrs